Common Biomarkers

Biomarker testing looks for specific genetic changes that can help guide treatment for cholangiocarcinoma. If your tumor has one of these biomarkers, your doctor may recommend a therapy or clinical trial designed to target it.

FGFR2: Changes in the FGFR2 gene can drive tumor growth. Targeted therapies that block this pathway may help slow or stop cancer progression.

IDH1: Mutations in the IDH1 gene affect how cells produce energy. Drugs that inhibit IDH1 activity may help stop tumor growth.

HER2: Overexpression of the HER2 protein can cause cancer cells to grow more quickly. Targeted HER2 therapies are available for some patients.

MSI-H or dMMR: These biomarkers indicate that a tumor has trouble repairing DNA damage. Patients with MSI-H or dMMR tumors may respond well to immunotherapy.

NTRK: NTRK gene fusions are rare but can be treated with targeted drugs that block the abnormal signaling driving tumor growth.

Biomarker testing helps personalize treatment so you and your care team can explore every possible option.